Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial.
Advanced non–small cell lung cancer
BRCA mutation
Next-generation sequencing
PARP inhibitors
SAFIR trial
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
04
04
2020
revised:
17
05
2020
accepted:
03
06
2020
entrez:
30
9
2021
pubmed:
11
6
2020
medline:
11
6
2020
Statut:
epublish
Résumé
Molecular profiling is considered a standard of care in advanced NSCLC. A comprehensive next-generation sequencing panel can discover somatic or germline From April 2014 to March 2017, 600 newly diagnosed, Of 379 patients with a molecular profile discussed in a tumor molecular board, Pathogenic
Identifiants
pubmed: 34589950
doi: 10.1016/j.jtocrr.2020.100068
pii: S2666-3643(20)30091-6
pmc: PMC8474245
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100068Informations de copyright
© 2020 by the International Association for the Study of Lung Cancer.
Références
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Nat Rev Clin Oncol. 2015 Jan;12(1):27-41
pubmed: 25286972
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Hum Mutat. 2016 Dec;37(12):1318-1328
pubmed: 27633797
Clin Cancer Res. 2019 Feb 1;25(3):1087-1097
pubmed: 30413523
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Oncotarget. 2017 Jun 28;8(54):93149-93155
pubmed: 29190984
Oncogene. 2013 Nov 21;32(47):5377-87
pubmed: 23934192
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nucleic Acids Res. 2012 Jan;40(Database issue):D992-1002
pubmed: 22144684
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Oncologist. 2016 Jul;21(7):869-74
pubmed: 27306910
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Pathol Oncol Res. 2020 Jan;26(1):109-114
pubmed: 31721094
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Ann Oncol. 2014 Nov;25(11):2156-2162
pubmed: 25139550
J Pathol. 2011 Aug;224(4):564-74
pubmed: 21706479
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
JCO Precis Oncol. 2020;4:442-465
pubmed: 32903788
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
Hematol Oncol Clin North Am. 2010 Oct;24(5):799-814
pubmed: 20816575
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
J Clin Invest. 2019 Mar 1;129(3):1211-1228
pubmed: 30589644
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44
pubmed: 18656380
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579